William Blair Has Pessimistic View of BMY FY2027 Earnings

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Investment analysts at William Blair dropped their FY2027 earnings estimates for Bristol-Myers Squibb in a report released on Tuesday, April 22nd. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings per share of $6.44 for the year, down from their previous forecast of $6.54. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $6.74 per share.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm's revenue was down 5.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($4.40) earnings per share.

A number of other research firms have also recently issued reports on BMY. UBS Group reduced their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Piper Sandler initiated coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. Truist Financial lifted their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Finally, Jefferies Financial Group reduced their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Stock Up 1.4 %

Shares of NYSE BMY traded up $0.69 during mid-day trading on Friday, reaching $49.91. The company had a trading volume of 5,548,273 shares, compared to its average volume of 12,936,540. The stock has a fifty day moving average of $56.11 and a two-hundred day moving average of $56.45. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a market capitalization of $101.56 billion, a price-to-earnings ratio of -11.29, a PEG ratio of 2.07 and a beta of 0.41. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be issued a dividend of $0.62 per share. The ex-dividend date is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 4.97%. Bristol-Myers Squibb's payout ratio is 92.88%.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The shares were bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.09% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Pinney & Scofield Inc. bought a new position in shares of Bristol-Myers Squibb during the 4th quarter worth about $25,000. Park Square Financial Group LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $26,000. Global Wealth Strategies & Associates increased its stake in Bristol-Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 275 shares during the period. Transce3nd LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $28,000. Finally, Fairway Wealth LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $28,000. Institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.